Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.56
NAVB's Cash to Debt is ranked higher than
58% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. NAVB: 0.56 )
NAVB' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: 0.56

Equity to Asset -1.01
NAVB's Equity to Asset is ranked lower than
57% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NAVB: -1.01 )
NAVB' s 10-Year Equity to Asset Range
Min: -3.6   Max: 0.94
Current: -1.01

-3.6
0.94
F-Score: 5
Z-Score: -22.74
M-Score: 6.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1476.21
NAVB's Operating margin (%) is ranked lower than
56% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 6.93 vs. NAVB: -1476.21 )
NAVB' s 10-Year Operating margin (%) Range
Min: -35429.11   Max: 13.25
Current: -1476.21

-35429.11
13.25
Net-margin (%) -1702.43
NAVB's Net-margin (%) is ranked lower than
57% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 5.11 vs. NAVB: -1702.43 )
NAVB' s 10-Year Net-margin (%) Range
Min: -36907.59   Max: 938.63
Current: -1702.43

-36907.59
938.63
ROA (%) -132.38
NAVB's ROA (%) is ranked lower than
57% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 3.49 vs. NAVB: -132.38 )
NAVB' s 10-Year ROA (%) Range
Min: -502.64   Max: 26.69
Current: -132.38

-502.64
26.69
ROC (Joel Greenblatt) (%) -1946.58
NAVB's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 12.42 vs. NAVB: -1946.58 )
NAVB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4904.17   Max: 145.59
Current: -1946.58

-4904.17
145.59
EBITDA Growth (%) -22.60
NAVB's EBITDA Growth (%) is ranked higher than
58% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -1.20 vs. NAVB: -22.60 )
NAVB' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 141
Current: -22.6

0
141
EPS Growth (%) -23.10
NAVB's EPS Growth (%) is ranked higher than
59% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. NAVB: -23.10 )
NAVB' s 10-Year EPS Growth (%) Range
Min: 0   Max: 112.7
Current: -23.1

0
112.7
» NAVB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013
Q4 2013
Q1 2014
Q2 2014
» Details

Insider Trades

Latest Guru Trades with NAVB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 66.00
NAVB's P/S is ranked lower than
51% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. NAVB: 66.00 )
NAVB' s 10-Year P/S Range
Min: 1.69   Max: 203
Current: 66

1.69
203
EV-to-EBIT -5.40
NAVB's EV-to-EBIT is ranked higher than
52% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 34.56 vs. NAVB: -5.40 )
NAVB' s 10-Year EV-to-EBIT Range
Min: -98.6   Max: -3.9
Current: -5.4

-98.6
-3.9
Current Ratio 3.34
NAVB's Current Ratio is ranked higher than
77% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NAVB: 3.34 )
NAVB' s 10-Year Current Ratio Range
Min: 0.65   Max: 17.92
Current: 3.34

0.65
17.92
Quick Ratio 3.03
NAVB's Quick Ratio is ranked higher than
80% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. NAVB: 3.03 )
NAVB' s 10-Year Quick Ratio Range
Min: 0.48   Max: 17.8
Current: 3.03

0.48
17.8

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 9.71
NAVB's Price/Median PS Value is ranked higher than
50% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 1.13 vs. NAVB: 9.71 )
NAVB' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 59.2
Current: 9.71

0.1
59.2
Earnings Yield (Greenblatt) -19.00
NAVB's Earnings Yield (Greenblatt) is ranked lower than
51% of the 391 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. NAVB: -19.00 )
NAVB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -19

Forward Rate of Return (Yacktman) 75.50
NAVB's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.44 vs. NAVB: 75.50 )
NAVB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -406.5   Max: 97.8
Current: 75.5

-406.5
97.8

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Navidea Biopharmaceuticals Inc is incorporated in Delaware. It is a biopharmaceutical company which is engaged in the development and commercialization of precision diagnostics and radiopharmaceutical agent. Its products include Gamma Detection Devices; Blood Flow Measurement Devices. Since October of 1999, its gamma detection systems have been marketed and distributed through Ethicon Endo-Surgery, Inc. 'EES', a Johnson & Johnson company. It has two radiopharmaceutical products, Lymphoseek and RIGScan, in advanced phases of clinical development. It faces competition from medical product and biotechnology companies, as well as from universities and other non-profit research organizations in the field of cancer diagnostics and treatment. As a developer, manufacturer and marketer of medical products, the Company is subject to regulation by, among other governmental entities, FDA and the corresponding state, local and foreign regulatory bodies in jurisdictions in which its products are sold.
» More Articles for NAVB

Headlines

Articles On GuruFocus.com
Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 
comment on NAVB Mar 15 2013 

More From Other Websites
Navidea Announces Scientific Presentations of Results from Lymphoseek® Studies at the European... Oct 30 2014
7:31 am Navidea Biopharma announces scientific presentations of results from Lymphoseek studies at... Oct 30 2014
Navidea Announces Scientific Presentations of Results from Lymphoseek® Studies at the European... Oct 30 2014
Navidea Announces Scientific Presentations of Results from Lymphoseek® Studies at the European... Oct 30 2014
Navidea Biopharmaceuticals to Announce Third Quarter 2014 Financial Results on November 6, 2014 Oct 29 2014
Navidea Biopharmaceuticals to Announce Third Quarter 2014 Financial Results on November 6, 2014 Oct 29 2014
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 16 2014
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 15 2014
Navidea Announces Rick Gonzalez as New Chief Executive Officer Oct 15 2014
Navidea Announces Rick Gonzalez as New Chief Executive Officer Oct 15 2014
FDA Approves Expanded Use of Navidea’s Lymphoseek® for Lymphatic Mapping in Solid Tumors Oct 15 2014
FDA Approves Expanded Use of Navidea’s Lymphoseek® for Lymphatic Mapping in Solid Tumors Oct 15 2014
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 01 2014
Navidea to Participate in the BTIG Emerging Technologies in Healthcare Diagnostics Investor... Sep 29 2014
Navidea’s Lymphoseek® Recommended by CHMP for European Approval in Sentinel Lymph Node Detection... Sep 26 2014
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 24 2014
Navidea Awarded $1.67M Fast Track NIH SBIR Grant for Evaluation of Lymphoseek® in Cervical Cancer Sep 23 2014
Navidea Receives Orphan Drug Designation from FDA for Use of Lymphoseek® in Head and Neck Cancers Sep 18 2014
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 10 2014
Should Navidea Biopharmaceuticals (NAVB) Be On Your Radar Now? Sep 10 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK